Medical News

RSS

Xencor licenses its XmAb and Xtend technology platforms to Centocor Research & Development

Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation and biosuperior antibodies, announced today that it has licensed its XmAb® and Xtend™ technology platforms to Centocor Research & Development, Inc. for the optimization of Centocor’s antibody drug candidates.

30 Nov 2009

Bavarian Nordic to file a NDS for IMVAMUNE with Health Canada

Bavarian Nordic A/S announced today that the company expects to file a New Drug Submission (NDS) for its third-generation smallpox vaccine, IMVAMUNE(R) with the Canadian Authorities, Health Canada in 2010. If successful, this would be the first marketing approval of IMVAMUNE(R).

30 Nov 2009

Kiadis Pharma commences enrollment in multinational ATIR study

Biopharmaceutical company Kiadis Pharma announces today that the first patients have been enrolled in its multinational registration clinical trial with ATIR(TM). The study is designed to show reduction in transplant related mortality (TRM) after one year following an allogeneic stem cell transplantation with a mismatched (haplo-identical) donor in blood cancer patients eligible for an allogeneic stem cell transplantation but without having a matched donor available.

30 Nov 2009

DALSA to showcase its Helios10 MD panel at the RSNA 2009

DALSA Corporation, through its Rad-icon Imaging division, today announced general availability of the Helios10 MD panel, the first product in the company's new Helios camera family. With an active area of 20 x 25 cm, the Helios10 MD is the first CMOS X-Ray panel from DALSA of this size and form factor, a medical-grade cassette package with an integrated handle.

30 Nov 2009

Allos Therapeutics granted U.S. patent for FOLOTYN

Allos Therapeutics, Inc. today announced that the United States Patent and Trademark Office has issued a patent for the use of FOLOTYN™ (pralatrexate injection) for the treatment of T-cell lymphoma. U.S. Patent No. 7,622,470 was issued to Memorial-Sloan Kettering Cancer Center, SRI International and Southern Research Institute, and expires on November 24, 2025.

30 Nov 2009

Eli Lilly's Cymbalta receives FDA approval

The U.S. Food and Drug Administration (FDA) has approved Cymbalta® (duloxetine HCl) for the maintenance treatment of generalized anxiety disorder (GAD) in adults, announced Eli Lilly and Company (NYSE: LLY).

30 Nov 2009

Acsys Interactive's recommendations to the FDA on social media in the healthcare industry

At the invitation of the Food and Drug Administration, Stan Valencis, President of Acsys Interactive, recently presented a series of recommendations to help shape the government's policy towards the promotion of prescription drugs, biologics and medical devices using the Internet and social media tools. As a leader in providing digital marketing and interactive strategies to healthcare systems, hospitals, device manufacturers and pharmaceutical companies, Acsys Interactive was selected by the FDA to provide its uniquely qualified perspective and experience.

30 Nov 2009

MHI team performs catheter implantation of the new Amptlazer Cardiac Plug prosthesis

A multidisciplinary team from the Montreal Heart Institute (MHI) performed its first catheter implantation of a new prosthesis (Amptlazer(R) Cardiac Plug) closing the appendage of the left atrium of the heart, which will have the effect of preventing the formation of blood clots and avoiding open-heart surgery. This is excellent news for patients suffering from atrial fibrillation, the most common form of cardiac arrhythmia, affecting at least 5% of Canadians over the age of 70.

30 Nov 2009

NanoViricides announces filing of its quarterly report with the SEC

NanoViricides, Inc., reports that the Company has filed its quarterly report with the SEC on November 23rd.

30 Nov 2009

Covidien sells its Oxygen Therapy product line to Chart Industries

Covidien, a leading global provider of healthcare products, today announced that it had completed the previously announced sale of its Oxygen Therapy assets to Chart Industries, Inc.. Financial terms of the transaction were not disclosed.

From Chart Industries 30 Nov 2009

Micromet to present new results from its blinatumomab study at the ASH meeting

Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will present new results from its clinical studies with blinatumomab at the 51st annual meeting of the American Society of Hematology from December 5-8, 2009 in New Orleans, Louisiana.

30 Nov 2009

ALS research collaboration receives philanthropic funding

Three prominent philanthropic organizations – The Angel Fund, The ALS Therapy Alliance and Project ALS -- dedicated to finding a treatment for amyotrophic lateral sclerosis (ALS) have financed a new collaboration between one of the world’s leading ALS researchers and RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi).

30 Nov 2009

Spectrum Pharmaceuticals completes enrollment in apaziquone Phase 3 trial

Spectrum Pharmaceuticals today announced that one of the two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target, having enrolled approximately 800 patients with non-invasive bladder cancer. The second Phase 3 clinical trial of apaziquone is expected to complete enrollment by the end of the year.

30 Nov 2009

Gentium announces financial results for the third quarter ended September 30, 2009

Gentium S.p.A. today reported financial results for the quarter ended September 30, 2009.

30 Nov 2009

Presentations at Tuesday's RSNA conference

A new study from Cincinnati Children's Hospital Medical Center reports that beverage can stay-tabs pose a potential ingestion risk. In the 1970s, U.S. manufacturers switched to the stay-tab design after safety concerns about pull-tabs. The new study found 19 cases of stay-tab ingestion at a single institution, mainly among teenagers.

30 Nov 2009

Free HIV testing marathon at Miami

To commemorate World AIDS Day 2009, AIDS Healthcare Foundation (AHF) will host a 12-hour free HIV testing marathon at its newest “Out of the Closet” Thrift Store in Miami at 2900 N. Biscayne Blvd. Tuesday, December 1st, from 8:00 a.m. to 8:00 p.m.

30 Nov 2009

Neurotechnology releases upgraded multi-biometric and AFIS systems

Neurotechnology, a provider of high-precision biometric identification technologies, has released two new upgrades in the company's core product line: VeriLook 4.0 Software Development Kit (SDK) for facial recognition and MegaMatcher 3.1 SDK for large-scale multi-biometric and automated fingerprint identification systems (AFIS). Expanded capabilities in VeriLook 4.0 provide enhanced facial recognition reliability across a wider range of facial positions.

30 Nov 2009

First Edition: November 30, 2009

In today's headlines, much attention is focused on the Senate as that chamber begins what is expected to be a stormy health overhaul debate.

30 Nov 2009

Medipattern, Sentinelle Medical sign technology access and distribution agreement

The Medipattern Corporation (TSX VENTURE:MKI), a pioneer in the development of medical software solutions that help improve imaging workflow and productivity and Sentinelle Medical Inc., a leading manufacturer of magnetic resonance imaging (MRI) coils and advanced visualization software, have announced that they are entering a technology access and distribution agreement.

30 Nov 2009

Cardiac Science, eClinicalWorks announce partnership

Cardiac Science Corporation, a global leader in automated external defibrillator (AED) and diagnostic cardiac monitoring devices that connect to electronic medical record (EMR) and hospital information systems, today announced a partnership with eClinicalWorks, a leading provider of EMR systems.

30 Nov 2009